On the other side, Momenta's management has not been forth coming enough with the complexity of working with the FDA to get approval of bio-similar. I see Enoxaparin as a one off event, that they could not even protect with their legal team, thus the difficulty with anything related to Copaxone. Lots of drugs get fast tracked and then fail miserably in stage 2 or 3 trials. If they believed in their own hype , why do Baxter starting trials with their bio similar for Humira, shows lack of belief in fingerprint technology of a drug for approval only.. So these are some obstacles they have to overcome IMHO. Still long , but not following blindly.
Somebody is going to snap this one up and SOON! I see an easy double to $26 coming for it. Then we have their proprietary drug candidate that has been fast tracked?? This should be a $20 plus stock right now with its current prospects
There is too much here for someone not to pull the trigger. The Cancer compound potential is enormous aside from the Biosim, I see a offer at the $24-26 happening very soon. That's an opinion
Todays antibodies are somewhat successful in preventing build up of protein deposits, but can't take out the ones that are already in the brain of Alzheimers patients...
If they can "beef-up" or tailor an antibody with a reduced effector function and make it 10X better, like they said they can, and chip away at these preexisting deposits as well as prevent new ones from forming... then Alzheimers is history... imho.. aloha k
copaxone will be decided any MOMENTa now...
the Hs-IVIg program is preclinical... the value will be unlocked with partnerships... however, if copaxone is approved and they do an at risk launch, Momenta will have the power to finance their development programs... k
Any short that covered will hate it when this keeps dropping into single digits. Management continues to show bad legal skills and lacking of understanding when it comes to the FDA procedures for bio-similar approval. Even though the patent ends in Sept this year-No FDA approval is the killer.
RCS Capital "RCAP"
CITI Initiated Coverage
With A $19 Target
on strong growth,
now $10.30 !
Shorts tried to take er
down to the 52 week low
the last few days in weak mkts,
they failed to do so!
"MNTA" Now has the
MOMO to the
4 awhile. . .
Sentiment: Strong Sell
the need for plasma will be greatly reduced... doctors will have in their hands a consistently super effective Hs-IVIg. Not only that they don't have to worry about pathogens getting into the supply... k
I am completely at lost for words... man I didn't even know that MNTA has this in its pipeline in the scope that I learned about it this weekend... I must have listened at least 4 times at their cached October investor presentation ... and multiple times in the following 4 presentations... I also skim/read several preclinical papers about it.... Necuparanib is a real gem... it has orphan designation, it is fast tracked since December because of the phenomenal phase 1 and 2a results... they are dosing in phase 2b now with 5mg/kg... trial size is 150 patients which makes it high powered... i'd like to think that the chances are very very good in an accelerated approval... dream... dream... dream... please come true!... k
in the recent presentations, they made it known that they want to let the pipeline mature first so that we shareholders get the best value... but hey, if someone wants to offer me $35 now I would be okay with it... at the end of the year I will want more.... aloha k
they are looking for a partner - $$$ - also in news, fda approves first biosimilar - approvial for generic copaxone most likely on its way...... biosimilars is where it's at.......
they have over 70 patents.. and if you look at their presentations and cc especially the investor day cc... you will find that they are pioneering this process...
and in the abstract regarding this process they are saying to their knowledge no one has done this before.. take an IVIg lot (this time from Baxster) and do their magic to it... from regular IVIg to s4-IVIg... give IR a call... aloha k